Vulvovaginal Candidiasis (VVC) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Vulvovaginal Candidiasis (VVC) occurs when Candida species superficially penetrate the mucosal lining of the vagina and cause an inflammatory response. The dominant inflammatory cells are typically polymorphonuclear cells and macrophages. Patients may present with discharge, which is usually thick and adherent, excoriations, external dysuria, vaginal itching, vaginal burning, dyspareunia, or swelling. Risk factors for acute candidal vulvovaginitis include estrogen use, elevated endogenous estrogens, diabetes mellitus, immunosuppression, and broad-spectrum antibiotic use. Although candidal vulvovaginitis is more common in sexually active women, there is no evidence that candidal infection is sexually transmitted. Patients with recurrent candidal vulvovaginitis have predisposing genetic factors that cause them to be susceptible to recurrent fungal infections. These factors may also predispose to hypersensitivity to Candida. The most common responsible pathogen is C. Albicans (in about 90% of cases), with most remaining instances caused by Candida glabrata.

 

Around 1 million outpatient visits to treat vaginal candidiasis, amongst which ~8% to 10% of patients reported recurrent candidal vulvovaginitis.

 

The competitive landscape of Vulvovaginal Candidiasis (VVC) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Vulvovaginal Candidiasis (VVC) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Vulvovaginal Candidiasis (VVC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Vulvovaginal Candidiasis (VVC) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Ibrexafungerp   Scynexis, Inc.   Phase 3

2          Prof-001           ProFem GmbH  Phase 2

3          Venus 20          EMS     Phase 2

4          SHR8008 capsule         Jiangsu HengRui Medicine Co., Ltd.            Phase 3

5          Miconazole Nitrate 2% + Domiphen Bromide       Aesculape CRO Belgium BV Phase 2

6          Oteseconazole (VT-1161)          Mycovia Pharmaceuticals Inc.            Phase 3

7          VT-1161           Viamet  Phase 2

8          NDV-3A            NovaDigm Therapeutics, Inc.     Phase 1

9          Lcr Regenerans Probionov         Phase 3

10        MAT2203 and MAT2501            Matinas BioPharma Nanotechnologies, Inc. Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more